Literature DB >> 21643487

Intracellular delivery of RNA-based therapeutics using aptamers.

Kristina W Thiel1, Paloma H Giangrande.   

Abstract

The clinical potential of siRNAs for silencing genes critical to disease progression is clear, but a fail-proof method for delivering siRNAs to the cytoplasm of diseased tissues or cells has yet to be identified. A variety of delivery approaches have been explored to directly or indirectly couple siRNAs to delivery vehicles. This review explores the use of synthetic single-stranded DNA and RNA aptamers as a means to deliver siRNAs, shRNAs and antisense oligonucleotides for therapeutic intervention. Topics covered include: the advantages and challenges of using aptamers as delivery tools; current aptamer-mediated siRNA delivery platforms for the treatment of cancer and HIV; and emerging methodologies for the identification of aptamers capable of internalizing into target cell types.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21643487      PMCID: PMC3106310          DOI: 10.4155/tde.10.61

Source DB:  PubMed          Journal:  Ther Deliv        ISSN: 2041-5990


  94 in total

1.  The path to personalized medicine.

Authors:  Margaret A Hamburg; Francis S Collins
Journal:  N Engl J Med       Date:  2010-06-15       Impact factor: 91.245

2.  An apt approach.

Authors:  Alan Dove
Journal:  Nat Med       Date:  2010-03       Impact factor: 53.440

3.  Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras.

Authors:  James O McNamara; Eran R Andrechek; Yong Wang; Kristi D Viles; Rachel E Rempel; Eli Gilboa; Bruce A Sullenger; Paloma H Giangrande
Journal:  Nat Biotechnol       Date:  2006-06-25       Impact factor: 54.908

4.  Derivation of RNA aptamer inhibitors of human complement C5.

Authors:  G Biesecker; L Dihel; K Enney; R A Bendele
Journal:  Immunopharmacology       Date:  1999-05

5.  Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs.

Authors:  Jürgen Soutschek; Akin Akinc; Birgit Bramlage; Klaus Charisse; Rainer Constien; Mary Donoghue; Sayda Elbashir; Anke Geick; Philipp Hadwiger; Jens Harborth; Matthias John; Venkitasamy Kesavan; Gary Lavine; Rajendra K Pandey; Timothy Racie; Kallanthottathil G Rajeev; Ingo Röhl; Ivanka Toudjarska; Gang Wang; Silvio Wuschko; David Bumcrot; Victor Koteliansky; Stefan Limmer; Muthiah Manoharan; Hans-Peter Vornlocher
Journal:  Nature       Date:  2004-11-11       Impact factor: 49.962

6.  Refocusing the war on cancer: the critical role of personalized treatment.

Authors:  Anil Potti; Richard L Schilsky; Joseph R Nevins
Journal:  Sci Transl Med       Date:  2010-04-21       Impact factor: 17.956

7.  Pharmacokinetics and biodistribution of novel aptamer compositions.

Authors:  Judith M Healy; Scott D Lewis; Markus Kurz; Ryan M Boomer; Kristin M Thompson; Charles Wilson; Thomas G McCauley
Journal:  Pharm Res       Date:  2004-12       Impact factor: 4.200

8.  Modulation of oncogenic transcription and alternative splicing by beta-catenin and an RNA aptamer in colon cancer cells.

Authors:  Hee Kyu Lee; Yong Seok Choi; Young Ae Park; Sunjoo Jeong
Journal:  Cancer Res       Date:  2006-11-01       Impact factor: 12.701

9.  The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells.

Authors:  Sridharan Soundararajan; Weiwei Chen; Eleanor K Spicer; Nigel Courtenay-Luck; Daniel J Fernandes
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

10.  Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy.

Authors:  Jiehua Zhou; Haitang Li; Shirley Li; John Zaia; John J Rossi
Journal:  Mol Ther       Date:  2008-05-06       Impact factor: 11.454

View more
  30 in total

1.  Cell-penetrating RNAs: new keys to the castle.

Authors:  Donald H Burke
Journal:  Mol Ther       Date:  2012-02       Impact factor: 11.454

2.  Inhibition of receptor signaling and of glioblastoma-derived tumor growth by a novel PDGFRβ aptamer.

Authors:  Simona Camorani; Carla L Esposito; Anna Rienzo; Silvia Catuogno; Margherita Iaboni; Gerolama Condorelli; Vittorio de Franciscis; Laura Cerchia
Journal:  Mol Ther       Date:  2014-01-02       Impact factor: 11.454

3.  An in Vitro Selection Strategy Identifying Naked DNA That Localizes to Cell Nuclei.

Authors:  John Smestad; Brandon Wilbanks; Louis J Maher
Journal:  J Am Chem Soc       Date:  2019-11-12       Impact factor: 15.419

4.  RNA aptamers and their therapeutic and diagnostic applications.

Authors:  Katherine Germer; Marissa Leonard; Xiaoting Zhang
Journal:  Int J Biochem Mol Biol       Date:  2013-03-31

5.  A U87-EGFRvIII cell-specific aptamer mediates small interfering RNA delivery.

Authors:  Xingmei Zhang; Huiyu Liang; Yan Tan; Xidong Wu; Shuji Li; Yusheng Shi
Journal:  Biomed Rep       Date:  2014-05-15

6.  Cell-internalization SELEX: method for identifying cell-internalizing RNA aptamers for delivering siRNAs to target cells.

Authors:  William H Thiel; Kristina W Thiel; Katie S Flenker; Tom Bair; Adam J Dupuy; James O McNamara; Francis J Miller; Paloma H Giangrande
Journal:  Methods Mol Biol       Date:  2015

7.  Multifunctional aptamer-miRNA conjugates for targeted cancer therapy.

Authors:  Carla L Esposito; Laura Cerchia; Silvia Catuogno; Gennaro De Vita; Justin P Dassie; Gianluca Santamaria; Piotr Swiderski; Gerolama Condorelli; Paloma H Giangrande; Vittorio de Franciscis
Journal:  Mol Ther       Date:  2014-01-20       Impact factor: 11.454

Review 8.  Manipulating the in vivo immune response by targeted gene knockdown.

Authors:  Judy Lieberman
Journal:  Curr Opin Immunol       Date:  2015-07-03       Impact factor: 7.486

9.  Prodrug strategy for PSMA-targeted delivery of TGX-221 to prostate cancer cells.

Authors:  Yunqi Zhao; Shaofeng Duan; Xing Zeng; Chunjing Liu; Neal M Davies; Benyi Li; M Laird Forrest
Journal:  Mol Pharm       Date:  2012-05-01       Impact factor: 4.939

Review 10.  Current progress on aptamer-targeted oligonucleotide therapeutics.

Authors:  Justin P Dassie; Paloma H Giangrande
Journal:  Ther Deliv       Date:  2013-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.